B7-33
Single-chain relaxin analog. Fibrosis and cardiac research; limited human data.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Advanced
What B7-33 is used for
- Single-chain relaxin analog — fibrosis + cardiac research
- Anti-fibrotic mechanism of interest
How it's typically used
Research range: ~0.1 mg subcutaneous daily.
What to watch for
- Very limited human data
- No established protocol
- Research-only; experimental
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
B7-33: A Tracking Guide for a Single-Chain Relaxin Analog
What B7-33 is, why it is studied in fibrosis and cardiac research, and why human tracking is currently very limited.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.